Medication info

Linagliptin/Metformin Duo Tablet 2.5/1000mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
Bright pink, convex, oval film-coated tablets on both sides
Packaging
60 tablets (10 tablets/PTP packaging x 6)
Approval status
Expired

MFDS item code 201905851 · Approved 2019.08.19

This product's status changed to Expired on 2024.08.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently treated with metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administer with caution to the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Difficulty in controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. It may be administered to patients who have no prior experience with diabetes drug therapy or who find it difficult to control blood sugar with monotherapy. It is added to treatment when adequate blood sugar control cannot be achieved with metformin alone or in combination with other medications. This medication helps enhance blood sugar control in combination with insulin, sulfonylureas, empagliflozin, and others.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently treated with metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administer with caution to the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication may cause rare but serious side effects such as lactic acidosis due to one of its active ingredients, metformin hydrochloride. The risk of lactic acidosis is higher in conditions of renal impairment, acute infection, dehydration, or severe trauma; therefore, this medication should not be used in those situations. Additionally, individuals who are allergic to any of the components included in this medication, have type 1 diabetes, diabetic ketoacidosis, severe renal impairment, acute alcohol intoxication, are pregnant, or nursing should not take this medication. When this medication is used in conjunction with sulfonylureas or insulin, there may be an increased risk of hypoglycemia, so blood glucose levels should be carefully monitored, and adjustments to the doses of other medications may be necessary. Elderly patients with decreased kidney function or those taking medications that may impact kidney function should have regular kidney function tests performed before and during treatment with this medication. Skin reactions such as acute pancreatitis or similar dermatitis may occur. If persistent and severe abdominal pain or skin blisters develop, immediate medical attention should be sought. This medication may lower vitamin B12 levels, so in cases of prolonged use, blood tests should be done to check vitamin B12 status, and supplementation should be considered if needed. Women who are pregnant or planning to become pregnant should avoid using this medication, and it is also advisable for nursing women not to take this medication. This medication can interact with other drugs, especially those that affect renal function or blood glucose levels, so it is important to consult a doctor when taking such medications together. Overdosage can lead to serious conditions like lactic acidosis, and immediate hospital treatment should be sought; typically, hemodialysis may be necessary. Lastly, the safety of this medication in children has not been established, and there are no studies on its effects on driving or operating machinery, so caution is advised. It is important to adhere to the precautions mentioned above during the use of this medication and to consult a healthcare provider at once if any unusual symptoms arise.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased vitamin B12 and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 124 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • dermatitis herpetiformis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • constipation
  • epigastric pain
  • dyspepsia
  • stomatitis
  • gastroesophageal reflux disease
  • gastritis
  • viral upper respiratory infection
  • upper respiratory infection
  • periodontitis
  • influenza
  • mediastinitis
  • pharyngitis
  • rhinitis
  • dizziness
  • sensory impairment
  • drowsiness
  • chest pain
  • fever
  • fatigue
  • discomfort in the chest
  • asthenia
  • nosebleed
  • oropharyngeal pain
  • chronic obstructive pulmonary disease
  • voice disorder
  • allergic rhinitis
  • exertional dyspnea
  • productive cough
  • asthma
  • rhinorrhea
  • lung mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • androgenetic alopecia
  • diabetic foot disease
  • hyperhidrosis
  • hair loss
  • skin lesions
  • dermatitis
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • meniscus injury
  • foot fracture
  • hand fracture
  • pneumoconiosis
  • laceration
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • palpitations
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • acute kidney injury
  • polyuria
  • proteinuria
  • end-stage renal disease
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • hearing loss
  • vertigo
  • erectile dysfunction
  • goiter
  • kidney transplant failure
  • anemia
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • altered mental status
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to store it at room temperature between 1°C and 30°C to maintain the drug's effectiveness over time.

Appearance and packaging

Appearance

Bright pink, convex, oval film-coated tablets on both sides

Package unit

60 tablets (10 tablets/PTP packaging x 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.